SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked to anticipation of founder Patrick Soon-Shiongs Piper Sandler oncology symposium chat, where he is expected to discuss trial progress; traders are also watching for updates on bladder-cancer programs and international expansion. Some bullish posts speculate about a partnership or short squeeze, but those claims remain unverified.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is drawing attention around its Coinbase listing and Midnights network rollout, including Google Clouds validator involvement. Traders welcome the added access and infrastructure milestones, though reactions are mixed as some see room for a recovery while others point to weak follow-through and nearby resistance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing attention around volatile price action, with traders debating whether its apparent resilience versus Bitcoin can lead to a recovery or breakout. Some point to the planned CashVM/Layla upgrade as a potential catalyst, while skeptics highlight BCHs underperformance, weak perceived utility, and risk of further declines.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding plan to acquire its first U.S. data center and expand its AI infrastructure footprint is drawing attention. Some traders view the move as strategic growth, while many question how it will be financed and whether the company can execute, with those concerns accompanying the selloff.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile plans to become a wireless carrier have fueled concern that T-Mobile could face greater long-term competition, contributing to a sharp selloff in telecom stocks. Traders are divided between viewing SpaceX as a future threat and calling the reaction excessive because building a competitive terrestrial network would require substantial investment and time.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

RYCEY is drawing attention amid a persistent pullback, with traders debating whether the weakness reflects market and geopolitical pressure or a change in the companys outlook. Long-term bulls point to aerospace and defense demand, Rolls-Royces India engine plans and SMR prospects, while speculation about an unannounced hyperscaler deal remains a recurring source of anticipation and skepticism.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange delisting concerns and JASMYs weak, volatile price action are driving debate, with some traders warning of further downside while others say specific exchange changes are being misrepresented or are limited in scope. Bulls also point to rising JasmyChain activity and ecosystem development as signs of emerging utility, though skeptics question whether that activity will translate into meaningful adoption or token demand.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Uncertainty over NASAs delayed CLPS 2.0 lunar-contract awards is the main focus, with traders watching for a decision and debating whether Intuitive Machines could benefit. Bulls view a contract as a potential catalyst, while bears point to repeated delays, a persistent downtrend, and weakness across space stocks.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, citing Palantirs sovereign-AI and customized-software growth opportunities, is fueling attention alongside a breakout to new highs. Bulls are celebrating the momentum and speculating about a short squeeze, while skeptics argue the valuation is stretched and warn of a pullback.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVAs rally is drawing attention amid the companys higher revenue outlook and expectations for upcoming melanoma, sarcoma and lung-cancer updates. Traders also point to a reported decline in short interest as a possible source of buying pressure, while others warn that the sharp run-up could give way to volatility and debate whether the NSCLC update will arrive on schedule.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK Pharma India Shareholders Approve Appointment of CFO Ronojit Biswas via Postal Ballot

GlaxoSmithKline Pharmaceuticals Limited ( ($IN:GLAXO) ) just unveiled an announcement. GlaxoSmithKline Pharmaceuticals Limited has concluded a post...

GSK Pharma Slapped Rs 23.21 Crore Tax Demand, Plans Appeal

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma ) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.

GST Blow: Maharashtra Authorities Slap Rs 6.92 Crore Tax Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received a tax demand … portal and was received physically. GlaxoSmithKline Pharmaceuticals Limited stated that the tax demand …

MP GST Dept Slaps Rs 3.79 Crore Tax, Penalty Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received … and documentation requirements. GlaxoSmithKline (GSK) Pharmaceuticals Limited clarified in its … appropriate action as necessary. GlaxoSmithKline Pharmaceuticals Limited, the Indian subsidiary …

GSK India plans big 'reinvention'

Mumbai: Global biopharma major GlaxoSmithKline Pharmaceuticals, best known in India for its blockbuster legacy brands Augmentin and Calpol, is charting a bold comeback in the country. The London-headquartered company, which has completed over a century in India's pharma market, is plotting its most ambitious transformation in decades as it targets doubling its India revenue to ₹8,000 crore within 4-5 years, India MD Bhushan Akshikar told ET in an exclusive interview.This will be driven by a strategic pivot from its ₹4,000-crore base of legacy portfolio of general medicines-including medications in anti-infective, pain management, respiratory and vaccines-into specialty drugs in high-growth areas of oncology and liver diseases as well as nascent areas such as adult vaccination."Reinvention and impact are the two words that define our journey in India. Taking cue from our past but remaining completely focused on the future is how I see the next decade for us," said Akshikar. "Our base business will continue to grow while on top of that we are launching in areas where we can make a sizeable impact," he added.The bet will be on innovation-led growth, accelerated clinical trials in India, and concurrent launches of global assets to double size by the end of the decade.

GSK Pharma to Procure 4.95 MWp Solar Power from CleanMax in Maharashtra

GlaxoSmithKline Pharmaceuticals (GSK Pharma ) will procure 4.95 MWp … , Syngene International, a Bengaluru-based pharmaceutical company, announced procuring renewable energy … February 2025, Mumbai-based Aarti Drugs partnered with Prozeal Green Energy …

GSK Pharma to Procure Power from CleanMax’s 4.95 MW Solar Project

GlaxoSmithKline Pharmaceuticals (GSK) has announced it will source power from a 4.95 MW solar project of Clean Max Galapagos, a special purpose vehicle (SPV) of CleanMax, in Maharashtra.

Top Diwali 2025 Picks: ICICI Bank, Varun Beverages, Finolex Among Nirmal Bang’s Favorites

Equity

From banking to beverages, Nirmal Bang’s Diwali portfolio highlights eight stocks poised for durable growth.

Mapping India’s Pharma Supply Chain Amid Shifting Global Currents

… materials, particularly active pharmaceutical ingredients (APIs) … , Executive Vice President, GlaxoSmithKline Pharmaceuticals ; Ajay Bagga, Managing … – Operations, Mankind Pharma ; Sreenivas Rao Nandigam, … Forecasting Failures in Pharma , Medical Device …

GSK re-enters India’s cancer drug market

GlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gynaecological cancers. This move marks a strategic pivot for GSK, aiming to establish a significant oncology presence in India. The company will import these therapies, focusing on access and affordability through tiered pricing and patient assistance programs.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. Its prescription medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and respiratory diseases. The vaccines products include prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others. The company was founded in 1924 and is headquartered in Mumbai, India.

Feed

News

Sentiment

Fundamentals

Info

GLAXO.NSE GlaxoSmithkline Pharmaceuticals Ltd

Latest GLAXO.NSE News